论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Chen J, Lv Y, Mu F, Xu K
Received 12 January 2019
Accepted for publication 22 February 2019
Published 5 April 2019 Volume 2019:12 Pages 2531—2538
DOI https://doi.org/10.2147/OTT.S200414
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Jyoti Bajaj
Peer reviewer comments 2
Editor who approved publication: Dr Sanjay Singh
Abstract: In this
study, we present the case of a 56-year-old patient with renal clear cell
carcinoma who developed lung metastases 13 months after nephrectomy and
subsequently received tyrosine kinase inhibitor (sunitinib) and PD-1 antibody
(nivolumab) immunotherapy, which failed to control the progression of the
disease. The patient further developed metastases to the left pleura, bilateral
hilar lymph nodes, liver, right lower kidney, scapula, left sixth rib, right
tonsil, and other organs. There was severe anemia, requiring weekly blood
transfusions. Karnofsky score was 30. After receiving mixed bacterial vaccine
(MBV) consisting of 6 kinds of heat-inactivated bacteria plus Poly I:C, the
patient’s condition rapidly improved, systemic metastases gradually reduced in
size or disappeared, anemia was corrected, and the patient was able to resume
normal life and work. MBV treatment in the setting of failure of previous
immunotherapy treatment appears to have achieved objective response for this
patient with metastatic renal clear cell carcinoma, which has lasted more than
20 months.
Keywords: mixed
bacterial vaccine, metastatic renal clear cell carcinoma